News | July 09, 2024
Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher
Shares and American Depositary Shares of Olink for $26.00 per Share
Shares and American Depositary Shares of Olink for $26.00 per Share
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Combined entity is better positioned to compete in increasingly competitive generics industry
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
The Issue opened on June 18, 2024 and closed on June 21, 2024
This strategic decision will unlock significant value for our scientific and industrial products business
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
